Study in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
This study is completed in the United Kingdom, in Switzerland, in Austria, .... It is testing Omega-3 fatty acids for Ultra High Risk for Psychosis.
SchizophreniaDrugFrom 13 Years to 20 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Omega-3 fatty acids may be useful for people experiencing schizophrenia.
What would participation involve?
Participants may receive Omega-3 fatty acids, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Austria, in Germany, and in Israel.
Who is it mainly for?
This study appears to be mainly for people with schizophrenia. Because it may involve minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Austria · 1 site
BioPsyC Biopsychosocial Corporation
Vienna
Site status: Not listed — confirm with the team
Germany · 1 site
Department of Child and Adolescent Psychiatry, University of Tübingen
Tübingen
Site status: Not listed — confirm with the team
Israel · 2 sites
Schneider Children's Medical Center
Petah Tikva
Site status: Not listed — confirm with the team
Tel Hashomer The Sheba Medical Center
Ramat Gan
Site status: Not listed — confirm with the team
Italy · 2 sites
Fondazione Santa Lucia
Rome
Site status: Not listed — confirm with the team
Sapienza University of Rome
Rome
Site status: Not listed — confirm with the team
Netherlands · 1 site
Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht
Utrecht
Site status: Not listed — confirm with the team
Norway · 1 site
Institute of Clinical Medicine, University of Bergen
Bergen
Site status: Not listed — confirm with the team
Spain · 4 sites
Hospital Clinic de Barcelona
Barcelona
Site status: Not listed — confirm with the team
Hospital Infantil Passeig Sant Joan de Deu
Barcelona
Site status: Not listed — confirm with the team
Hospital General Universitario Gregorio Marañon
Madrid
Site status: Not listed — confirm with the team
Idival, University of Cantabria, Cibersam Unidad de investigacion en psiquiatria
Santander
Site status: Not listed — confirm with the team
Switzerland · 1 site
ZKJP University Zürich
Zurich
Site status: Not listed — confirm with the team
United Kingdom · 1 site
Psychiatry, Centre for Clinical Brain Sciences
Edinburgh
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Omega-3 fatty acids, Placebo. Phase 4 studies usually happen after treatment approval, to monitor real-world use.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 13 Years to 20 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Rene Kahn, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
